Yun-Ha Hwang

Title: Innovations of Yun-Ha Hwang in Osteoporosis Treatment

Introduction

Yun-Ha Hwang is a notable inventor based in Ansan-si, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of osteoporosis. With a total of 5 patents to his name, Hwang's work is recognized for its innovative approach to addressing this prevalent health issue.

Latest Patents

Hwang's latest patents include the use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for the prophylaxis and treatment of osteoporosis. This invention relates to a pharmaceutical composition that utilizes these derivatives to effectively prevent and treat osteoporosis. Specifically, it focuses on the use of 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine or its N-hydroxy counterpart as a key component in the treatment regimen. Another patent describes a method of treating osteoporosis by administering a composition that includes the compound 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine or a salt thereof. This method also emphasizes the inhibition of osteoclast activity while stimulating osteoblast activity in patients.

Career Highlights

Yun-Ha Hwang is currently associated with Dong Wha Pharmaceutical Co. Ltd., where he continues to innovate in the pharmaceutical sector. His work has garnered attention for its potential to improve the quality of life for individuals suffering from osteoporosis.

Collaborations

Hwang collaborates with esteemed colleagues, including Jei Man Ryu and Jin Soo Lee, who contribute to his research and development efforts. Their combined expertise enhances the potential impact of their innovations in the field.

Conclusion

Yun-Ha Hwang's contributions to osteoporosis treatment through his innovative patents highlight the importance of research in pharmaceuticals. His work not only addresses a critical health issue but also showcases the potential for advancements in medical treatments.